Announcing our newest cancer test. Screen cancer early with Onco-D-clare. Learn more
Our newest Onco-D-clare test takes a proactive step towards early cancer detection and your informed well-being. This test is uniquely tailored for people without symptoms but with a desire for early intervention.
With the ease of a simple blood draw, you can now detect cancer long before any symptoms emerge. Onco-D-clare opens an early door to personalized health insights.
Onco-D-clare analyzes the details of your gene expressions by combining gene expression analysis and machine learning algorithms.
The Onco-D-clare test goes beyond traditional screening, aiming to detect cancer at its earliest stages. This revolutionary screening test goes beyond established norms, comprehensively analyzing your cancer risk even before your body shows any signs.
Early cancer detection allows for proactive management, increasing the chances of successful intervention and treatment. With over 90 genes analyzed as part of the Onco-D-clare test, it generates a comprehensive gene expression profile, empowering you with detailed information for informed decision-making.
The Onco-D-clare test begins with a simple blood draw, which is an efficient way to start your cancer screening process. This test acts as a proactive measure, providing personalized screening for those who seek to stay ahead of potential health challenges.
The Onco-D-clare test is designed as an early screening test for patients who do not have a cancer diagnosis but may want to stay informed about their risk. This is especially useful for those who have a family history of cancer or other risk factors.
The Onco-D-clare test has shown remarkable reliability of results. It has been clinically validated with an approximate accuracy of 93%, ensuring that its insights are rooted in precision and scientific rigor.
When it comes to cancer care, knowledge is a powerful tool. The Onco-D-clare test empowers you with knowledge by offering a nuanced understanding of your cancer risk and the means to chart a proactive course toward a healthier future.
Blood draw results are usually available in 7-10 days, making this advanced cancer screening test accessible, efficient, and affordable.
All our accredited practitioners understand our shipping instructions and ensure the sample arrives in perfect condition.
Price in Euros: € 800
Disclaimer:
* Prices in $USD vary slightly based on the exchange rate on the day the test is ordered.
** These prices do not include in-office fees such as consultation, blood draws, IV administration, etc.
To know what to expect from the test results, view a sample Onco-D-clare test result here.
Your sample will be processed at our state-of-the-art laboratory in Greece. Once the test is completed, we will provide a detailed breakdown of our findings. The results are sent to your registered practitioner, who downloads the results and sets up an appointment with you to go over the results.
Our scientists use world-leading technology, equipment, and innovative techniques to develop a range of cancer screening and monitoring tests. Knowledge is empowerment, especially when it comes to your health.
Our early cancer screening tests provide a comprehensive understanding of your cancer risk even before symptoms emerge. This information helps you make informed decisions about your well-being.
Contact us online for this proactive step today and help pave the way for a healthier and more empowered tomorrow.
Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.
In this insightful interview from the 2023 RGCC Gathering, Dr. Clayton Bell shares his journey of integrating RGCC technologies into his practice in the U.S.
With a background in Functional, Environmental, and Integrative Medicine, Dr. Bell reveals how he uses RGCC’s cutting-edge cancer diagnostics and therapies to support his patients’ healing. Watch the full video to learn more.
Helena Pöhlmann who specializes in holistic medicine shares how she utilizes RGCC products in her clinic to best support her patients. Watch the video to learn about her experience at the 2023 RGCC Gathering in Switzerland.
Cancer survivor and RGCC Practitioner, Jenny Hrbaceck, discusses RGCC testing and the impact it has made on her life.
Watch an interview with Dr. Bita Badakhshan, a seasoned practitioner in primary family medicine with over 12 years of experience in integrative oncology and functional medicine.
In this video, Dr. Bita shares her experience with RGCC’s transformative liquid biopsy testing. She highlights the unparalleled precision and detail offered by RGCC's advanced methodologies over other laboratories.
Dr. Bita emphasizes the unmatched sensitivity of RGCC's testing, which delves deep into analyzing stem cells, cancer cells, and a comprehensive array of markers crucial for personalized cancer care.
Since 2012, Dr. Beta has trusted RGCC for blood testing on patients, particularly focusing on circulating tumor cell analysis and using RGCC’s Oncocount and Oncotrace tests along with the Onconomics Plus assessments.
Through RGCC's innovative tests and therapies, Dr. Bita has been able to make informed decisions sparing many patients from unnecessary chemotherapy and radiation post-tumor removal surgeries.
Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.
Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.
Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.
Explore our curated collection of videos, providing an in-depth look at our innovative solutions and groundbreaking research.
In this insightful interview from the 2023 RGCC Gathering, Dr. Clayton Bell shares his journey of integrating RGCC technologies into his practice in the U.S.
With a background in Functional, Environmental, and Integrative Medicine, Dr. Bell reveals how he uses RGCC’s cutting-edge cancer diagnostics and therapies to support his patients’ healing. Watch the full video to learn more.
Helena Pöhlmann who specializes in holistic medicine shares how she utilizes RGCC products in her clinic to best support her patients. Watch the video to learn about her experience at the 2023 RGCC Gathering in Switzerland.
Cancer survivor and RGCC Practitioner, Jenny Hrbaceck, discusses RGCC testing and the impact it has made on her life.
Watch an interview with Dr. Bita Badakhshan, a seasoned practitioner in primary family medicine with over 12 years of experience in integrative oncology and functional medicine.
In this video, Dr. Bita shares her experience with RGCC’s transformative liquid biopsy testing. She highlights the unparalleled precision and detail offered by RGCC's advanced methodologies over other laboratories.
Dr. Bita emphasizes the unmatched sensitivity of RGCC's testing, which delves deep into analyzing stem cells, cancer cells, and a comprehensive array of markers crucial for personalized cancer care.
Since 2012, Dr. Beta has trusted RGCC for blood testing on patients, particularly focusing on circulating tumor cell analysis and using RGCC’s OncoCount and OncoTrace tests along with the Onconomics Plus assessments.
Through RGCC's innovative tests and therapies, Dr. Bita has been able to make informed decisions sparing many patients from unnecessary chemotherapy and radiation post-tumor removal surgeries.
Read more about our therapies on our website: https://rgcc-international.com/rgcc-therapies/
RGCC was launched in 2004 by genetics pioneer Dr. Ioannis Papasotiriou who believes that the key to effectively treating cancer lies in personalized medicine using the information in a patient’s genes.
Individualized treatment for cancer is the focus behind RGCC’s testing protocols and advanced therapy options. Our slate of tests analyzes the state of a person’s cancer by looking at the cellular and genetic makeup of each patient. Our test results give you information that acts as a blueprint for what treatment protocols are likely to show the most efficacy for your specific biology.
Learn more about RGCC at
https://rgcc-international.com/
Follow us on social media to find out the latest news and updates from our experts.
Facebook: https://www.facebook.com/profile.php?id=61554630098937
Instagram: https://www.instagram.com/rgcc_north_america/
LinkedIn: https://www.linkedin.com/company/r-g-c-c-international-gmbh/
Join host Sam Tejada for an essential conversation about cancer innovation and breakthroughs on this episode of A Healthy Point of View, including a close look at advances in early cancer detection - as early as stage ZERO.
Tejada sits down with two leading medical experts: Dr. Christopher Davis, an interventional cardiologist and CMO of Liquivida, and Dr. Ioannis Papasotiriou, MD, PhD, SCym, the founder of RGCC.
Together, they tackle one of medicine's most complex challenges, sharing cutting-edge insights and breakthrough approaches that could transform how we understand and address cancer care.
